P2.06-024 Tedopi vs Standard Treatment as 2nd or 3rd Line...

Journal of Thoracic Oncology 2017 / 01 Vol. 12; Iss. 1

P2.06-024 Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1

Besse, Benjamin, Le Moulec, Sylvestre, Mazieres, Julien, Pouessel, Damien, Albert, Istvan, Romano, Giampiero, Girard, Nicolas, Pichon, Eric, Molinier, Olivier, Chouaid, Christos, Corre, Romain, Remon,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
12
Language:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1016/j.jtho.2016.11.1517
Date:
January, 2017
File:
PDF, 331 KB
english, 2017
Conversion to is in progress
Conversion to is failed